Landmark independent study reports significantly improved task performance and satisfaction and lowe

Landmark independent study reports significantly improved task performance and satisfaction and lowe

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept.

Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical

Experienced leadership team to build on established commercial platform and accelerate Lifeward's ne

Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimat

Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst conse

Revenue increase and operating performance improve as capital-efficient distribution strategy gains

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LF

The agreement brings together Lifeward’s advanced personal exoskeleton technology and Ottobock Care’

Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , brin

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restor

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan

Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation m

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate

Oramed  strategic transaction successfully closed and $10 million financing received Oratech acquisi

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFW

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past si

Lifeward Ltd. (NASDAQ: LFWD - Get Free Report) shares were up 2.5% on Thursday. The stock traded as

Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innova

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Bu

Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript

Lifeward (NASDAQ:LFWD) reported quarterly losses of $(2.85) per share which missed the analyst conse

Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath t

Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability

Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and

Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innov

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal E

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Bu

Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in inno

Lifeward (NASDAQ:LFWD) affirms FY2025 sales outlook from $24.000 million-$26.000 million to $24.000

Lifeward (NASDAQ:LFWD) reported quarterly losses of $(0.19) per share which beat the analyst consens